The possible future roles for iPSC-derived therapy for autoimmune diseases

14Citations
Citations of this article
40Readers
Mendeley users who have this article in their library.

Abstract

The ability to generate inducible pluripotent stem cells (iPSCs) and the potential for their use in treatment of human disease is of immense interest. Autoimmune diseases, with their limited treatment choices are a potential target for the clinical application of stem cell and iPSC technology. IPSCs provide three potential ways of treating autoimmune disease; (i) providing pure replacement of lost cells (immuno-reconstitution); (ii) through immune-modulation of the disease process in vivo; and (iii) for the purposes of disease modeling in vitro. In this review, we will use examples of systemic, system-specific and organ-specific autoimmunity to explore the potential applications of iPSCs for treatment of autoimmune diseases and review the evidence of iPSC technology in auto-immunity to date.

Cite

CITATION STYLE

APA

Hew, M., O’Connor, K., Edel, M. J., & Lucas, M. (2015, May 28). The possible future roles for iPSC-derived therapy for autoimmune diseases. Journal of Clinical Medicine. MDPI. https://doi.org/10.3390/jcm4061193

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free